NASDAQ: SION

Sionna Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for SION. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Sionna Therapeutics, Inc. (NASDAQ: SION) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 07:14 UTC.

What Sionna Therapeutics, Inc. does

This clinical-stage biopharmaceutical company develops medicines for cystic fibrosis by targeting the CFTR protein, specifically a part called the NBD1 domain that had not been directly addressed by existing therapies. The company focuses on the F508del mutation, which affects a substantial portion of CF patients. Its pipeline includes lead candidates SION-719 and SION-451, which stabilize NBD1, along with complementary modulators designed to work together to improve CFTR function.

Summarized from Sionna Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Charts

Charts are in the appInteractive charts for SION are available in Oxford Ledge.
Open SION in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-09-21

2026-09-21DirectorSale-33,800$252.1K
2026-09-21DirectorSale-3,415,011$21.58M
2026-09-18CFO and CBOAward47,269—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

RA CAPITAL MANAGEMENT, L.P.9,905,045$435.72M0.0%
TPG GP A, LLC6,494,962$285.71M0.0%
VIKING GLOBAL INVESTORS LP3,195,181$140.56M0.0%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2026-09-14Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersStark BeerAuthoritativeSEC 8-K →

Company news

View all →

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
globenewswire.com2026-09-29NEG
Sionna Therapeutics, Inc. (SION) Discusses Post-Hoc Analysis of PreciSION CF Trial and Advancement of Dual Combination Program Transcript
Seeking Alpha Feed2026-09-15
INVESTIGATION ALERT: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - SION
prnewswire.com2026-08-27NEG
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
globenewswire.com2026-08-26NEG
Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics
prnewswire.com2026-08-19NEG

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for SION and 5,000+ tickers.

Create a free account — keep SION

For your agent

GET /api/data?ticker=SION

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt